

Duchenne Muscular Dystrophy (DMD) Market Size in the 7MM to Reach USD 3,906.1 Million by 2035

The report also provides a detailed analysis of the current Duchenne muscular dystrophy marketed drugs and late-stage pipeline drugs.

BROOKLYN, NY, UNITED STATES, June 30, 2025 /EINPresswire.com/ -- How big is the market for Duchenne muscular dystrophy?

The <u>Duchenne muscular dystrophy</u> (<u>DMD</u>) market size reached a value of USD 2,259.0 million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3,906.1 Million by

The market is exhibiting a

CONTINUOUS growth rate

Market Opportunity (USD)

Duvyzat (givinostat) - Italfarmaco

Elevidy; (delandistrogene mosparvovec-rokl)

- Savepta Threapeutics

Emifaza (deflazacort) - Marathon
Pharmaceuticals/PTC Therapeutics

- Eteplizen (Exondys 51) - Sarepta Therapeutics

Eteplizen (Exondys 51) - Sarepta Therapeutics

- PTCI24 (Ataluren) - PTC Therapeutics

- PTCI24 (Ataluren)

Duchenne Muscular Dystrophy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

2035, exhibiting a growth rate (CAGR) of 5.11% during 2025-2035.

Duchenne muscular dystrophy is a rare genetic disease that weakens muscles progressively. The DMD market in 2025 includes gene and molecular therapies, corticosteroids, exon-skipping drugs, cell-based treatments, and supportive care. Growing awareness and urgent need for effective treatments drive innovation in this market.

Market Drivers Fueling Growth

Rising prevalence of DMD and improved genetic screening have expanded the diagnosed patient pool. Regulatory support—including orphan drug designations, fast-track approvals, and conditional approvals—is accelerating therapy launches. Also, increasing private and public funding for R&D, along with strong pipeline momentum, underpins rapid growth.

Key Trends in 2025

Gene therapy is transforming DMD treatment. Sarepta's Elevidys, the first approved gene therapy for ambulatory DMD patients, expanded to non ambulatory cases in late 2024, though safety

concerns have since emerged, prompting an FDA review after reports of liver-related deaths. Meanwhile, cell therapies like Capricor's deramiocel, exon-skipping treatments from PTC Therapeutics, and new corticosteroids such as vamorolone (Agamree) and the HDAC inhibitor givinostat (Duvyzat) are advancing through approvals and early access programs.

By 2025, the DMD market is evolving into a dynamic field defined by cutting-edge genetic and molecular therapy options. While gene therapy promises a transformative impact, safety monitoring remains critical. Emerging therapies such as exon skipping drugs, corticosteroids with improved safety profiles, and cell based approaches reinforce a more diversified treatment landscape. Regulatory backing and expanding patient access indicate a powerful shift toward better outcomes and sustained market growth in the coming decade.

Request for a sample of this report: https://www.imarcgroup.com/duchenne-muscular-dystrophy-market/requestsample

The report also provides a detailed analysis of the current Duchenne muscular dystrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Competitive Landscape with key players:

The competitive landscape of the Duchenne muscular dystrophy market has been studied in the report with the detailed profiles of the key players operating in the market.

Italfarmaco
Sarepta Therapeutics
Marathon Pharmaceuticals/PTC Therapeutics
REGENXBIO

Edgewise Therapeutics

7 Major Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Elena Anderson IMARC Services Private Limited +1 631-791-1145 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/827005764

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.